Table 2.
Baseline characteristics and history of the disease by type of tumour
| Breast cancer (N = 31) | Prostate cancer (N = 21) | Lung cancer (N = 41) | |
|---|---|---|---|
| Sex, n (%) | |||
| Female | 28 (90.3) | 0 (0.0) | 13 (31.7) |
| Male | 3 (9.7) | 21 (100.0) | 28 (68.3) |
| Age (years) | |||
| Median (range) | 56 (38–79) | 68 (50–86) | 59 (35–80) |
| Age group, n (%) | |||
| <65 years | 20 (64.5) | 7 (33.3) | 26 (63.4) |
| ≥65 years | 11 (35.5) | 14 (66.7) | 15 (36.6) |
| ECOG performance status, n (%) | |||
| 0 | 6 (19.4) | 6 (28.6) | 7 (17.1) |
| 1 | 12 (38.7) | 10 (47.6) | 17 (41.5) |
| 2 | 13 (41.9) | 5 (23.8) | 17 (41.5) |
| History of SREs, n (%)a | |||
| Yes | 20 (64.5) | 14 (66.7) | 27 (65.9) |
| No | 11 (35.5) | 7 (33.3) | 14 (34.1) |
| Time from the diagnosis of the primary tumour to recruitment (months) | |||
| Median (range) | 62.7 (0.6–259.9) | 68.3 (0.6–261.2) | 3.5 (0.3–49.1) |
| Time from the diagnosis of the bone metastasis to recruitment (months) | |||
| Median (range) | 4.86 (0.2–125.1) | 11.10 (0.2–107.6) | 1.81 (0.0–34.2) |
| Duration of prospective follow-up (months) | |||
| Median (range) | 6.87 (0.2–18.2) | 4.63 (0.5–17.7) | 2.60 (0.2–17.3) |
| Type of follow-up for all SREsb | |||
| Prospective, n (%) | 11 (23.4) | 16 (44.4) | 11 (18.3) |
| Retrospective, n (%) | 36 (76.6) | 20 (55.6) | 49 (81.7) |
| Prior bisphosphonate use, n (%) | 21 (67.8) | 11 (52.4) | 16 (39.0) |
| Time from first administration to recruitment (months) | |||
| Median (Q1, Q3) | 6.0 (2.5, 35.1) | 5.5 (1.4, 8.6) | 0.9 (0.4, 1.7) |
SREs skeletal-related events, ECOG eastern cooperative oncology group
aPatients suffering any SRE in a period prior to recruitment of over 97 days
bPercentages calculated based on number of SREs